Karyopharm Therapeutics (KPTI) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Karyopharm Therapeutics Revenue Highlights

Latest Revenue (Y)

$145.24M

Latest Revenue (Q)

$30.02M

Main Segment (Y)

License and Service

Main Geography (Y)

CANADA

Karyopharm Therapeutics Revenue by Period

Karyopharm Therapeutics Revenue by Year

Date	Revenue	Change
2024-12-31	$145.24M	-0.55%
2023-12-31	$146.03M	-7.03%
2022-12-31	$157.07M	-25.14%
2021-12-31	$209.82M	94.12%
2020-12-31	$108.08M	164.31%
2019-12-31	$40.89M	34.80%
2018-12-31	$30.34M	1790.09%
2017-12-31	$1.60M	942.21%
2016-12-31	$154.00K	-38.40%
2015-12-31	$250.00K	9.17%
2014-12-31	$229.00K	-40.83%
2013-12-31	$387.00K	-38.96%
2012-12-31	$634.00K	317.11%
2011-12-31	$152.00K	-

Karyopharm Therapeutics generated $145.24M in revenue during NA 2024, up -0.55% compared to the previous quarter, and up 355.16% compared to the same period a year ago.

Karyopharm Therapeutics Revenue by Quarter

Date	Revenue	Change
2025-03-31	$30.02M	-1.73%
2024-12-31	$30.54M	-21.25%
2024-09-30	$38.78M	-9.36%
2024-06-30	$42.79M	29.16%
2024-03-31	$33.13M	-1.84%
2023-12-31	$33.75M	-6.28%
2023-09-30	$36.01M	-4.18%
2023-06-30	$37.58M	-2.89%
2023-03-31	$38.70M	15.24%
2022-12-31	$33.58M	-7.10%
2022-09-30	$36.15M	-8.91%
2022-06-30	$39.68M	-16.76%
2022-03-31	$47.67M	-62.25%
2021-12-31	$126.27M	235.03%
2021-09-30	$37.69M	66.76%
2021-06-30	$22.60M	-2.83%
2021-03-31	$23.26M	-33.73%
2020-12-31	$35.10M	64.53%
2020-09-30	$21.33M	-36.35%
2020-06-30	$33.51M	84.77%
2020-03-31	$18.14M	0.23%
2019-12-31	$18.10M	37.62%
2019-09-30	$13.15M	38.51%
2019-06-30	$9.49M	6024.52%
2019-03-31	$155.00K	-24.76%
2018-12-31	$206.00K	-13.81%
2018-09-30	$239.00K	-98.80%
2018-06-30	$19.89M	98.91%
2018-03-31	$10.00M	551.89%
2017-12-31	$1.53M	100.00%
2017-09-30	-	-100.00%
2017-06-30	$3.00K	-95.59%
2017-03-31	$68.00K	44.68%
2016-12-31	$47.00K	-2.08%
2016-09-30	$48.00K	-18.64%
2016-06-30	$59.00K	100.00%
2016-03-31	-	-100.00%
2015-12-31	$25.00K	-66.67%
2015-09-30	$75.00K	-50.00%
2015-06-30	$150.00K	100.00%
2015-03-31	-	-100.00%
2014-12-31	$15.00K	-28.57%
2014-09-30	$21.00K	-
2014-06-30	$21.00K	-87.72%
2014-03-31	$171.00K	714.29%
2013-12-31	$21.00K	100.00%
2013-09-30	-	-100.00%
2013-06-30	$133.00K	-42.92%
2013-03-31	$233.00K	606.06%
2012-12-31	$33.00K	-2.94%
2012-09-30	$34.00K	-

Karyopharm Therapeutics generated $30.02M in revenue during Q1 2025, up -1.73% compared to the previous quarter, and up 88.94% compared to the same period a year ago.

Karyopharm Therapeutics Revenue Breakdown

Karyopharm Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
License and Service	$28.01M	$24.36M	$15.67M	-	-
Health Care, Other	$2.74M	-	-	-	-
Royalty	-	$1.50M	$300.00K	-	-
License	-	$3.50M	-	-	-
License And Other	-	-	-	$111.38M	$31.88M
Product	-	-	-	$98.44M	$76.21M

Karyopharm Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License and Service (91.10%), and Health Care, Other (8.90%).

Quarterly Revenue by Product

Product/Service	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
Health Care, Other	$113.00K	$2.29M	$241.00K	$203.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License and Service	$8.20M	$12.86M	$8.75M	$6.41M	$4.45M	$5.56M	$5.61M	$8.74M	$437.00K	$1.62M	$6.53M	-	-	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	$1.50M	$400.00K	$200.00K	$1.00M	$1.40M	$1.00M	-	-	-	-	-	-	-	-	-
Other Royalty	-	-	-	-	-	$500.00K	$400.00K	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	-	-	-	-	-	-	-	-	-	-	-	$28.30M	$29.80M	$26.72M	$20.18M	$21.73M	$20.22M	$21.33M	$18.60M	$16.06M
License And Other	-	-	-	-	-	-	-	-	-	-	-	$19.37M	$96.47M	$10.97M	$2.42M	$1.53M	$14.88M	$3.00K	$14.91M	$2.08M

Karyopharm Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: License and Service (98.64%), and Health Care, Other (1.36%).

Karyopharm Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 20
CANADA	$5.00M

Karyopharm Therapeutics's latest annual revenue breakdown by geography, as of Dec 20: CANADA (100.00%).

Karyopharm Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
KPTI	Karyopharm Therapeutics	$145.24M	$30.02M
CTMX	CytomX Therapeutics	$138.10M	$50.92M
GOSS	Gossamer Bio	$114.70M	$9.89M
BLUE	bluebird bio	$83.81M	$38.52M
GLUE	Monte Rosa Therapeutics	$75.62M	$60.65M
MRSN	Mersana Therapeutics	$40.50M	$12.60M
AGIO	Agios Pharmaceuticals	$36.50M	$8.73M
GBIO	Generation Bio	$19.89M	$4.19M
KRON	Kronos Bio	$9.85M	$2.27M
NUVB	Nuvation Bio	$7.87M	$5.71M
XFOR	X4 Pharmaceuticals	$2.56M	$28.81M
LYRA	Lyra Therapeutics	$1.53M	$209.00K
RLYB	Rallybio	$636.00K	$38.00K
REPL	Replimune Group	-	-
ABOS	Acumen Pharmaceuticals	-	-
NVCT	Nuvectis Pharma	-	-
HOOK	HOOKIPA Pharma	-	-
ASMB	Assembly Biosciences	-	$7.36M
PMVP	PMV Pharmaceuticals	-	-
MREO	Mereo BioPharma Group	-	-

KPTI Revenue FAQ

What is Karyopharm Therapeutics’s yearly revenue?

Karyopharm Therapeutics's yearly revenue for 2024 was $145.24M, representing a decrease of -0.55% compared to 2023. The company's yearly revenue for 2023 was $146.03M, representing a decrease of -7.03% compared to 2022. KPTI's yearly revenue for 2022 was $157.07M, representing a decrease of -25.14% compared to 2021.

What is Karyopharm Therapeutics’s quarterly revenue?

Karyopharm Therapeutics's quarterly revenue for Q1 2025 was $30.02M, a -1.73% decrease from the previous quarter (Q4 2024), and a -9.39% decrease year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $30.54M, a -21.25% decrease from the previous quarter (Q3 2024), and a -9.50% decrease year-over-year (Q4 2023). KPTI's quarterly revenue for Q3 2024 was $38.78M, a -9.36% decrease from the previous quarter (Q2 2024), and a 7.70% increase year-over-year (Q3 2023).

What is Karyopharm Therapeutics’s revenue growth rate?

Karyopharm Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -7.54%, and for the last 5 years (2020-2024) was 34.37%.

What are Karyopharm Therapeutics’s revenue streams?

Karyopharm Therapeutics's revenue streams in c 24 are License and Service, and Health Care, Other. License and Service generated $28.01M in revenue, accounting 91.10% of the company's total revenue, up 15.00% year-over-year. Health Care, Other generated $2.74M in revenue, accounting 8.90% of the company's total revenue

What is Karyopharm Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Karyopharm Therapeutics was License and Service. This segment made a revenue of $28.01M, representing 91.10% of the company's total revenue.